Uterine lyomioma. Noninflammatory disorder of uterus, unspecified
Conditions
Interventions
Intervention 1: The intervention group 2 was consisted of 26 patients
they were treated using GnRH one dose per month (3.75mg intramuscular injection). Intervention 2: Intervention group 1 was consisted of 27 patients who were received a daily dose of raloxifene 60 mg/o
Treatment - Drugs
The intervention group 2 was consisted of 26 patients
they were treated using GnRH one dose per month (3.75mg intramuscular injection).
Intervention group 1 was consisted of 27 patients who were received a daily dose of raloxifene 60 mg/orally for 3 months.
Sponsors
Vice chancellor for research, Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: not being menopausal, and having a history of lyomiomas with a minimum size of 40 mm and a maximum of 60 mm in one of the diameters of tumor. Exclusion criteria: having metabolic disease, neoplasia disease, infectious diseases, blood disorders; history of venous thrombosis, liver disease, active rheumatoid arthritis; BMI greater than 30 or less than 18 kg/m2; hormone therapy in the last 6 months; surgery in the last 6 months; hypoechoic or calcified lyomiomas; endometrial abnormalities in sonography, and lesions of the cervix.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine leiomyomas size. Timepoint: Before and 90 days after treatment. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Endometrial thickness. Timepoint: Before and 90 days after treatment. Method of measurement: Sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Farhadifar
Kurdistan University of Medical Sciences
Outcome results
None listed